56979-56-7

Usage

Uses

Used in Organic Synthesis:
5-(benzyloxy)-2-hydroxybenzaldehyde is used as a building block for the synthesis of a variety of bioactive molecules. Its unique structure allows for the formation of complex organic compounds that can exhibit a range of biological activities.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 5-(benzyloxy)-2-hydroxybenzaldehyde is utilized as a key intermediate in the development of pharmaceuticals. Its reactivity and functional groups make it suitable for the synthesis of new drug candidates with potential therapeutic applications.
Used as a Reagent in Chemical Reactions:
5-(benzyloxy)-2-hydroxybenzaldehyde also serves as a reagent in various chemical reactions, facilitating the formation of desired products through its participation in condensation, oxidation, or other types of chemical transformations.
Used in Drug Discovery and Development:
Due to its structural features and properties, 5-(benzyloxy)-2-hydroxybenzaldehyde is employed as a starting material in drug discovery processes. It contributes to the development of new chemical entities with potential applications in treating various diseases and medical conditions.
Used in the Development of New Chemical Entities:
5-(benzyloxy)-2-hydroxybenzaldehyde is instrumental in the creation of novel chemical entities, which may lead to the discovery of innovative treatments and therapeutic strategies in the pharmaceutical industry. Its versatility and reactivity in chemical processes make it an invaluable asset in the synthesis of new compounds with potential medicinal value.

Upstream product

• 103-16-2 4-Benzyloxyphenol 
• 100-39-0 benzyl bromide 
• 50-00-0 formaldehyd 
• 1194-98-5 2,5-Dihydroxybenzaldehyde 
• 199185-75-6 C₂₆H₂₅NO₂ 
• 67-66-3 chloroform 
• 100-44-7 benzyl chloride 
• 6109-54-2 2,5-bis(benzyloxy)benzaldehyde 
• 23001-29-8 6-hydroxy spiropyran 

Downstream Products

• 52329-06-3 5-(benzyloxy)-2-methoxybenzaldehyde 
• 900781-10-4 5-(benzyloxy)-2-(t-butyldimethylsilyloxy)benzaldehyde 
• 853599-45-8 5-(benzyloxy)benzo[b]furan-2-carboxylic acid ethyl ester 
• 328919-31-9 2-(4-benzyloxy-2-formylphenoxy)-2-methyl propionic acid ethyl ester 
• 1206675-07-1 C₁₄H₁₃NO₃ 
• 1336839-82-7 (2R,3R,4R,4aR,5R,10aR)-3,4,7-tris(benzyloxy)-2-benzyloxymethyl-5-methoxy-2,3,4,4a,5,10a-hexahydropyrano[2,3-b]chromene 
• 99370-68-0 5-hydroxy-2-benzofuran-carboxylic acid ethyl ester 
• 912462-48-7 (5-(benzyloxy)benzofuran-2-yl)methanol 
• 1450913-92-4 5-(benzyloxy)-2-(ethoxymethyl)benzofuran 
• 6769-56-8 2-methyl-5-hydroxy-benzofuran 
• 279231-59-3 2-(ethoxymethyl)benzofuran-5-ol 
• 1450913-71-9 1-(2-(3-(2-(ethoxymethyl)benzofuran-5-yloxy)-2-hydroxypropylamino)ethyl)-3-(4-hydroxyphenyl)urea 

Relevant academic research and scientific papers

Novel Cyclic Phenoxy Compounds and Improved Treatments for Cardiac and Cardiovascular Disease

A compound of formula I, and its pharmaceutically acceptable salt or salts and physiologically hydrolysable derivatives in free form or salt form: wherein either Q1, CR6a and optionally R6b together form a cyclic moiety wh

6-Substituted 1,2-benzoxathiine-2,2-dioxides are isoform-selective inhibitors of human carbonic anhydrases IX, XII and VA

A series of 6-substituted 2-benzoxathiine-2,2-dioxides were synthesized starting from 2,5-dihydroxybenzaldehyde, and then screened in vitro for their inhibition properties against five human carbonic anhydrase (hCA, EC 4.2.1.1) isoforms. All the compounds

NOVEL CYCLIC PHENOXY COMPOUNDS AND IMPROVED TREATMENTS FOR CARDIAC AND CARDIOVASCULAR DISEASE

A compound of formula I, and its pharmaceutically acceptable salt or salts and physiologically hydrolysable derivatives in free form or salt form: (Formula (I)) wherein either Q1, CR6a and optionally R6b together form a cy

Discovery of hybrid dual N-acylhydrazone and diaryl urea derivatives as potent antitumor agents: Design, synthesis and cytotoxicity evaluation

Based on the hybrid pharmacophore design concept, a novel series of dual diaryl urea and N-acylhydrazone derivatives were synthesized and evaluated for their in vitro cytotoxicity by the standard MTT assay. The pharmacological results indicated that most compounds exhibited moderate to excellent activity. Moreover, compound 2g showed the most potent cytotoxicity against HL-60, A549 and MDA-MB-231 cell lines, with IC50 values of 0.22, 0.34 and 0.41 μM, respectively, which was 3.8 to 22.5 times more active than the reference compounds sorafenib and PAC-1. The promising compound 2g thus emerges as a lead for further structural modifications.

Polyoxygenated cinnamoylcoumarins as conformationally constrained analogs of cytotoxic diarylpentanoids: Synthesis and biological activity

A series of polyoxygenated cinnamoylcoumarins was synthesized as conformationally constrained analogs of cytotoxic diarylpentanoids. The title compounds were tested against the viability of human chronic myelogenous leukemia (K562), human acute lymphoblastic leukemia (MOLT-4) and human breast adenocarcinoma (MCF-7) cell lines by using MTT (3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) assay. Among them, all 6- or 7-hydroxylated compounds 6a-h exhibited remarkable cytotoxic activity. Particularly, 7-hydroxycoumarin analog 6h showed good antiproliferative activity against all tested cell lines (IC50 values ≤ 5.5 μM). The preliminary study with selected compounds 6e and 6f showed that reactivity towards mitochondrial thiol compounds cab be considered as cytotoxic mechanism of designed compounds. Furthermore, the antioxidant activity evaluation of synthesized compounds showed that hydroxylated compounds had antioxidative potential at higher concentrations.

Design, synthesis and anticancer activities of diaryl urea derivatives bearing N-acylhydrazone moiety

A new series of diaryl urea derivatives bearing N-acylhydrazone moiety were designed and synthesized. All the target compounds were evaluated for their cytotoxic activities in vitro against human lung adenocarcinoma epithelial cell line (A549), human breast cancer cell line (MDA-MB-231) and human leukemia cell line (HL-60) by standard 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Several compounds (1a, 1f and 1h) were further evaluated against human embryonic fibroblast, lung-derived cell line (WI38). The pharmacological results indicated that some compounds exhibited promising anticancer activities. In particular, compound 1f showed the most potent cytotoxicity against the tested three cell lines with IC50 values of 0.41 μM, 0.24 μM and 0.23 μM, respectively.

Characterization of scavengers of γ-ketoaldehydes that do not inhibit prostaglandin biosynthesis

Expression of cyclooxygenase-2 (COX-2) is associated with the development of many pathologic conditions. The product of COX-2, prostaglandin H2 (PGH2), can spontaneously rearrange to form reactive γ-ketoaldehydes called levuglandins (LGs). This γ-ketoaldehyde structure confers a high degree of reactivity on the LGs, which rapidly form covalent adducts with primary amines of protein residues. Formation of LG adducts of proteins has been demonstrated in pathologic conditions (e.g., increased levels in the hippocampus in Alzheimer's disease) and during physiologic function (platelet activation). On the basis of knowledge that lipid modification of proteins is known to cause their translocation and to alter their function, we hypothesize that modification of proteins by LG could have functional consequences. Testing this hypothesis requires an experimental approach that discriminates between the effects of protein modification by LG and the effects of cyclooxygenase-derived prostanoids acting through their G-protein coupled receptors. To achieve this goal, we have synthesized and evaluated a series of scavengers that react with LG with a potency more than 2 orders of magnitude greater than that with the ε-amine of lysine. A subset of these scavengers are shown to block the formation of LG adducts of proteins in cells without inhibiting the catalytic activity of the cyclooxygenases. Ten of these selective scavengers did not produce cytotoxicity. These results demonstrate that small molecules can scavenge LGs in cells without interfering with the formation of prostaglandins. They also provide a working hypothesis for the development of pharmacologic agents that could be used in experimental animals in vivo to assess the pathophysiological contribution of levuglandins in diseases associated with cyclooxygenase up-regulation.

Active core structure of terfestatin A, a new specific inhibitor of auxin signaling

The auxins, plant hormones, regulate many aspects of the growth and development of plants. Terfestatin A (TrfA), a novel auxin signaling inhibitor, was identified in a screen of Streptomyces sp. F40 extracts for inhibition of the expression of an auxin-in

ANTIFUNGAL AGENT CONTAINING PYRIDINE DERIVATIVE

The present invention provides an antifungal agent that has superior antifungal action and is also superior in terms of physical properties, safety and metabolic stability. The present invention discloses a compound represented by the formula (I): (wherein X represents an oxygen atom, a sulfur atom or -NH-, R1 represents a hydrogen atom, a halogen atom, a cyano group, an amino group or a substituent, and R2 and R3 independently represent a hydrogen atom, a halogen atom, a hydroxyl group or a substituent, except for a case in which R2 and R3 are both hydrogen atoms), and an antifungal agent containing the above compound.

Fischer's base as a protecting group: Protection and deprotection of 2- hydroxybenzaldehydes

The hydroxyl and aldehyde groups of 2-hydroxybenzaldehydes were protected by the reaction with Fischer's base and deprotected by the ozonolysis in methanol at -78°C to give the corresponding 2- hydroxybenzaldehydes in good to high yields. (C) 2000 Elsevier Science Ltd.